Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$74.83 USD

74.83
1,043,778

-0.25 (-0.33%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $74.78 -0.05 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Medtronic (MDT) Up 0.7% Since Last Earnings Report: Can It Continue?

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HAE or BSX: Which Is the Better Value Stock Right Now?

HAE vs. BSX: Which Stock Is the Better Value Option?

After Plunging -15.88% in 4 Weeks, Here's Why the Trend Might Reverse for Haemonetics (HAE)

Haemonetics (HAE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

HAE vs. BSX: Which Stock Is the Better Value Option?

HAE vs. BSX: Which Stock Is the Better Value Option?

Implied Volatility Surging for Haemonetics (HAE) Stock Options

Investors need to pay close attention to Haemonetics (HAE) stock based on the movements in the options market lately.

Haemonetics (HAE) Set to Launch VASCADE MVP XL in US

Haemonetics (HAE) expands its VASCADE portfolio with the full market release of the VASCADE MVP XL vascular closure device in the U.S. market.

Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises

Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.

Is Haemonetics (HAE) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Down -14.6% in 4 Weeks, Here's Why Haemonetics (HAE) Looks Ripe for a Turnaround

Haemonetics (HAE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

HAE or BSX: Which Is the Better Value Stock Right Now?

HAE vs. BSX: Which Stock Is the Better Value Option?

Haemonetics (HAE) Misses Q1 Earnings Estimates

Haemonetics (HAE) delivered earnings and revenue surprises of -0.97% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 30.13% Upside in Haemonetics (HAE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why Haemonetics (HAE) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Verano Holdings Corp. (VRNOF) Reports Q2 Loss, Lags Revenue Estimates

Verano Holdings Corp. (VRNOF) delivered earnings and revenue surprises of 0% and 0.82%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Align Technology (ALGN) Encounters Low ASP, FX Headwinds

Align Technology's (ALGN) Clear Aligner ASP is facing a significant impact of unfavorable foreign exchange across multiple currencies.

Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?

Phibro's (PAHC) Animal Health business, supported by the flourishing Vaccine product line, drives optimism for future growth. However, macroeconomic impacts are a concern.

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

Cerus (CERS) delivered earnings and revenue surprises of 25% and 6.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exact Sciences (EXAS) Q2 Loss Narrower Than Expected, Sales Beat

Exact Sciences' (EXAS) second-quarter 2024 top-line results reflect robust revenues from the Screening and Precision Oncology segments.

Baxter's (BAX) Helion Surgical System Debuts in Thailand

Baxter (BAX) launches the Helion Integrated Surgical System in Thailand, aiming to streamline operating room efficiency and enhance surgical team connectivity with cutting-edge technology.

Hospital Business Recovery to Aid Haemonetics' (HAE) Q1 Earnings

Haemonetics' (HAE) first-quarter fiscal 2025 results are likely to reflect the benefits of hemostasis management growth.

Hologic (HOLX) Buys Endomag to Boost Breast Cancer Solutions

Hologic (HOLX) acquires Endomag for $310M, enhancing its breast cancer surgery portfolio with innovative technologies like Magseed and Magtrace, aiming to improve patient care and outcomes globally.

ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand

ICON's (ICLR) second-quarter 2024 results reflect efficient service delivery and strong cost control.

Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms

Terumo's (TRUMY) subsidiary MicroVention's WEB 17 device, used in treating intracranial aneurysms, demonstrates high safety and effectiveness in the CLEVER study.

Align Technology (ALGN) Beats on Q2 Earnings, Lowers '24 Sales View

Align Technology's (ALGN) records second-quarter 2024 revenue growth across all regions. This was mostly due to a robust performance by the Imaging Systems & CAD/CAM Services business segment.